Bay of Plenty Times
  • Bay of Plenty Times home
  • Latest news
  • Business
  • Opinion
  • Lifestyle
  • Property
  • Sport
  • Video
  • Death notices
  • Classifieds

Subscriptions

  • Herald Premium
  • Viva Premium
  • The Listener
  • BusinessDesk

Sections

  • Latest news
  • On The Up
  • Business
  • Opinion
  • Lifestyle
  • Property
    • All Property
    • Residential property listings
  • Rural
    • All Rural
    • Dairy farming
    • Sheep & beef farming
    • Horticulture
    • Animal health
    • Rural business
    • Rural life
    • Rural technology
  • Sport

Locations

  • Coromandel & Hauraki
  • Katikati
  • Tauranga
  • Mount Maunganui
  • Pāpāmoa
  • Te Puke
  • Whakatāne
  • Rotorua

Media

  • Video
  • Photo galleries
  • Today's Paper - E-Editions
  • Photo sales
  • Classifieds

Weather

  • Thames
  • Tauranga
  • Whakatāne
  • Rotorua

NZME Network

  • Advertise with NZME
  • OneRoof
  • Driven Car Guide
  • BusinessDesk
  • Newstalk ZB
  • Sunlive
  • ZM
  • The Hits
  • Coast
  • Radio Hauraki
  • The Alternative Commentary Collective
  • Gold
  • Flava
  • iHeart Radio
  • Hokonui
  • Radio Wanaka
  • iHeartCountry New Zealand
  • Restaurant Hub
  • NZME Events

SubscribeSign In
Advertisement
Advertise with NZME.
Home / Bay of Plenty Times

Breast cancer: Pāpāmoa retiree with ‘incurable’ diagnosis calls for Enhertu drug funding

Megan Wilson
By Megan Wilson
Multimedia Journalist·Bay of Plenty Times·
9 Jun, 2025 09:46 PM5 mins to read

Subscribe to listen

Access to Herald Premium articles require a Premium subscription. Subscribe now to listen.
Already a subscriber?  Sign in here

Listening to articles is free for open-access content—explore other articles or learn more about text-to-speech.
‌
Save

    Share this article

Pāpāmoa retiree Marion Henriksen was diagnosed with advanced "incurable" HER2-low breast cancer in 2021. Photo / Supplied

Pāpāmoa retiree Marion Henriksen was diagnosed with advanced "incurable" HER2-low breast cancer in 2021. Photo / Supplied

Pāpāmoa retiree Marion Henriksen was meant to be travelling in Germany and Austria with a friend.

Instead, she had to cancel and spend $36,000 on an unfunded cancer drug due to her stage 4 breast cancer diagnosis.

The 70-year-old former school principal said she had used some of her life savings to pay for the drug Enhertu.

“I never expected to get sick in my retirement like this.

“I didn’t want to spend it on Enhertu drugs – I wanted to spend it on travelling.”

Advertisement
Advertise with NZME.
Advertisement
Advertise with NZME.

Henriksen acknowledged Pharmac had a fixed budget but believed Enhertu should be funded for the type of cancer she had – advanced HER2-low breast cancer – given it was funded for HER2-positive metastatic breast cancer.

The Breast Cancer Foundation New Zealand agreed and said more than 20 countries, including Australia, funded Enhertu for Henriksen’s type of breast cancer.

A foundation statement said people with HER2-low breast cancer made up 40% of advanced breast cancer patients in New Zealand.

Advertisement
Advertise with NZME.

“The evidence for Enhertu’s effectiveness in this group is strong, with the cancer remaining stable for 63% longer and survival extended by 36%.”

Pāpāmoa retiree Marion Henriksen was diagnosed with advanced 'incurable' HER2-low breast cancer in 2021. Photo / Supplied
Pāpāmoa retiree Marion Henriksen was diagnosed with advanced 'incurable' HER2-low breast cancer in 2021. Photo / Supplied

Henriksen said she was first diagnosed with breast cancer in 2009.

She had a partial mastectomy and radiation therapy, then took hormone therapy for seven years.

Henriksen said she was “cancer-free” for the next 11 years.

In 2021, she learned the cancer had returned and was diagnosed with advanced “incurable” HER2-low breast cancer.

She had several different treatments – some worked for a while, but they eventually stopped working.

Her oncologist recommended Enhertu, which she started taking in March.

She paid for three cycles of it, costing about $36,000.

By May, it was no longer working.

Henriksen’s oncologist recommended funded medication methotrexate and cyclonex, which she started taking at the end of May.

Advertisement
Advertise with NZME.

She was not yet sure of its effectiveness.

Henriksen thought about the people who could not afford Enhertu.

“I think all cancer patients should have access to whatever drugs are going to make a difference to extend their life.

“I suppose it kept me going for another two or three months.”

Henriksen said she had been referred to hospice again for the third time.

“The prognosis is not good, but whether I’ve got two days or two weeks or two months, no one knows.”

Advertisement
Advertise with NZME.

Henriksen said she was still maintaining a “pretty good quality of life”.

Her family had been “wonderfully supportive”, and she loved her garden and climbing Mauao.

The avid traveller said she had goals to “live life to the fullest”, including doing all of the Great Walks of New Zealand.

“I could have been in Austria and Germany at the moment with a friend who’s travelling, so I’ve had to pull out of quite a few things.”

Henriksen said she tried not to think about her prognosis.

“I just put it in the background until I have to deal with it.

Advertisement
Advertise with NZME.

“I live for the day.”

Breast Cancer Foundation New Zealand chief executive Ah-Leen Rayner. Photo / Supplied
Breast Cancer Foundation New Zealand chief executive Ah-Leen Rayner. Photo / Supplied

The foundation’s chief executive Ah-Leen Rayner said funding Enhertu would make a “monumental” difference, with clinical trials showing it offered an additional 4.8 months of “progression-free survival”.

“The impact on people’s finances having to pay for this themselves is significant.”

Rayner said Enhertu was a “standard of care” overseas.

“New Zealand needs access to the best quality treatments in line with other countries around the world, but instead New Zealand is languishing at the bottom of the OECD world for access to modern medicines.”

For breast cancer patients, “women are dying faster ... than women overseas”, she said.

Advertisement
Advertise with NZME.

Pharmac advice and assessment director and chief medical officer Dr David Hughes said it funded as many medicines as possible from its fixed budget.

“We acknowledge it is difficult when medicines aren’t funded and that cancer medicines are expensive.”

Hughes said it funded trastuzumab deruxtecan (branded as Enhertu) for people with HER2-positive metastatic breast cancer for the first time as of January 1, 2025.

Pharmac received a funding application in April 2024 for Enhertu for HER2-low breast cancer when the cancer could not be removed by surgery or had spread around the body.

In May 2025, Pharmac sought advice from the cancer treatment advisory committee about the application, Hughes said.

Pharmac was compiling the meeting’s record to publish online, which would include a committee recommendation about funding Enhertu.

Advertisement
Advertise with NZME.

It would keep in contact with key groups such as the Breast Cancer Foundation as the application progressed, Hughes said.

Depending on the recommendation, Pharmac’s next step would be to assess the application and rank it on one of Pharmac’s priority lists, he said.

“It’s important that we take the time to seek clinical advice and thoroughly assess all applications.

“Unfortunately, we’re unable to say if or when this application would be funded.”

Hughes said there would always be more medicines that Pharmac would like to fund.

While some medicines were available in other countries, “our funding and reimbursement systems are often not comparable”, he said.

Advertisement
Advertise with NZME.

“We need to make our own decisions about what to fund for New Zealanders.”

Megan Wilson is a health and general news reporter for the Bay of Plenty Times and Rotorua Daily Post. She has been a journalist since 2021.

Save

    Share this article

Latest from Bay of Plenty Times

Bay of Plenty Times

Te Puke take hard-fought win, Rotoiti claim Tai Mitchell Shield

09 Jun 11:07 PM
Bay of Plenty Times

Wellington leads in income, South Island shines in low unemployment

09 Jun 09:01 PM
Bay of Plenty Times

Whakaari alert level lowered as volcanic activity decreases

09 Jun 08:20 PM

Why Cambridge is the new home of future-focused design

sponsored
Advertisement
Advertise with NZME.

Latest from Bay of Plenty Times

Te Puke take hard-fought win, Rotoiti claim Tai Mitchell Shield

Te Puke take hard-fought win, Rotoiti claim Tai Mitchell Shield

09 Jun 11:07 PM

Round 10 of the Jordan Cup was won by Te Puke Sports over Greerton at Murray Salt Stadium.

Wellington leads in income, South Island shines in low unemployment

Wellington leads in income, South Island shines in low unemployment

09 Jun 09:01 PM
Whakaari alert level lowered as volcanic activity decreases

Whakaari alert level lowered as volcanic activity decreases

09 Jun 08:20 PM
Fog disrupts 43 flights at Auckland Airport, severe storms to follow

Fog disrupts 43 flights at Auckland Airport, severe storms to follow

09 Jun 07:33 PM
Clean water fuelling Pacific futures
sponsored

Clean water fuelling Pacific futures

NZ Herald
  • About NZ Herald
  • Meet the journalists
  • Newsletters
  • Classifieds
  • Help & support
  • Contact us
  • House rules
  • Privacy Policy
  • Terms of use
  • Competition terms & conditions
  • Our use of AI
Subscriber Services
  • Bay of Plenty Times e-edition
  • Manage your print subscription
  • Manage your digital subscription
  • Subscribe to Herald Premium
  • Subscribe to the Bay of Plenty Times
  • Gift a subscription
  • Subscriber FAQs
  • Subscription terms & conditions
  • Promotions and subscriber benefits
NZME Network
  • Bay of Plenty Times
  • The New Zealand Herald
  • The Northland Age
  • The Northern Advocate
  • Waikato Herald
  • Rotorua Daily Post
  • Hawke's Bay Today
  • Whanganui Chronicle
  • Viva
  • NZ Listener
  • What the Actual
  • Newstalk ZB
  • BusinessDesk
  • OneRoof
  • Driven CarGuide
  • iHeart Radio
  • Restaurant Hub
NZME
  • About NZME
  • NZME careers
  • Advertise with NZME
  • Digital self-service advertising
  • Book your classified ad
  • Photo sales
  • NZME Events
  • © Copyright 2025 NZME Publishing Limited
TOP